All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference Listing
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Trending News on Targeted Oncology, Week of March 27, 2020

Mar 27, 2020
Danielle Ternyila

Targeted Oncology reviews trending news and videos online for the week of March 27, 2020, including recent updates on the impact of COVID-19 in oncology practice and a clinical trial on breast cancer.

Experts such as Randall A. Oyer, MD, from Penn Medicine Lancaster General, and Kashyep Patel, MD, of the Carolina Blood and Cancer Center, spoke withTargeted Oncologyon the impact seen in their practices due to the COVID-19 pandemic. The Community Oncology Alliance (COA) also brought attention to concerns in the community.

Although the focus remains on COVID-19 and its impacts on oncology practice as a whole, the Annual Report to the Nation on the Status of Cancer demonstrated declines in cancer rate deaths and highlighted the importance of clinical advances.

These updates and others were trending this week:

Challenges for Clinical Trials and Treating Patients With Cancer in Light of the Coronavirus

In an interview withTargeted Oncology, Oyer discussed how his institution is handling the COVID-19 pandemic while still accommodating patients who are already enrolled on clinical trials. The opening of new trials and enrollment has been suspended at this time, but new patients may be enrolled on trials if the treatment is necessary. Precautions have been taken to keep both staff and patients safe during this time.

South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic

The spread of COVID-19 has impacted practices across the country, but Carolina Blood and Cancer Care has made adjustments to ensure the safety of their patients and staff while COVID-19 remains an issue. In an interview withTargeted Oncology, Patel discussed the implementation of new precautions in his practice as the number of COVID-19 cases rises in South Carolina.

Death By Cancer Shows Decline in the 2020 Annual Report to the Nation on the Status of Cancer

According to the Annual Report to the Nation on the Status of Cancer, which was published inCancer, cancer death rates continued to decline in the United States from 2001 to 2017 across all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016.

Additional data from the report related tothe Healthy People 2020 Initiativedemonstrated the importance of monitoring trends in cancer risk, screening test use, and mortality.

COA President Urges White House to Waive Prior Authorization Requirements for Cancer Treatment

In an open letter to the President of the United States, COA brought attention to the critical needs of patients with cancer, requesting all private health insurance companies immediately waive all “prior authorization” requirements for cancer treatments, which pose a threat to cancer treatment, particularly in patients who are elderly and among the most vulnerable in the United States to contract COVID-19.

Novel Immunotherapy Strategy Demonstrates Favorable Toxicity in Early-Stage Breast Cancer

Patients with early-stage breast cancer who received pelareorep demonstrated consistent findings with that of the safety run-in data and had a favorable toxicity profile, according to a cohort analysis from the window-of-opportunity study, AWARE-1 (NCT04102618).

Videos:

Atezolizumab and Bevacizumab Studied in Patients With Metastatic RCC

Bradley McGregor, MD, of Dana-Farber Cancer Institute, discussed a trial investigating atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with metastatic renal cell carcinoma (RCC) and variant histologies and/or sarcomatoid features.

Case Studies: A 56-Year-Old Female With Recurrent Ovarian Cancer

Related Videos
Experts on renal cell carcinoma
Related Content

Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer

June 9th 2023

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023

ASCO Seeks Clarity from FDA Draft Guidance to Improve Trials for Accelerated Approval

June 9th 2023

Anticipating Novel Options for the RAI-Refractory DTC Armamentarium

May 15th 2023

Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM

June 9th 2023

Adding Daratumumab to Transplant Therapy Meets Stem Cell Yield Goals, But Further Study Needed

June 9th 2023

Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer

June 9th 2023

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023

ASCO Seeks Clarity from FDA Draft Guidance to Improve Trials for Accelerated Approval

June 9th 2023

Anticipating Novel Options for the RAI-Refractory DTC Armamentarium

May 15th 2023

Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM

June 9th 2023

Adding Daratumumab to Transplant Therapy Meets Stem Cell Yield Goals, But Further Study Needed

June 9th 2023

Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer

June 9th 2023

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023

ASCO Seeks Clarity from FDA Draft Guidance to Improve Trials for Accelerated Approval

June 9th 2023

Anticipating Novel Options for the RAI-Refractory DTC Armamentarium

May 15th 2023

Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM

June 9th 2023

Adding Daratumumab to Transplant Therapy Meets Stem Cell Yield Goals, But Further Study Needed

June 9th 2023
Related Content

Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer

Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer

June 9th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.

Read More


Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen


ASCO Seeks Clarity from FDA Draft Guidance to Improve Trials for Accelerated Approval

ASCO Seeks Clarity from FDA Draft Guidance to Improve Trials for Accelerated Approval

June 9th 2023
Article

The Association for Clinical Oncology has provided recommendations to the FDA for its draft guidance, which reflects a strong preference for randomized controlled trials.

Read More


Anticipating Novel Options for the RAI-Refractory DTC Armamentarium

Anticipating Novel Options for the RAI-Refractory DTC Armamentarium

May 15th 2023
Podcast

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

Listen


Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM

Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM

June 9th 2023
Article

Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.

Read More


Adding Daratumumab to Transplant Therapy Meets Stem Cell Yield Goals, But Further Study Needed

Adding Daratumumab to Transplant Therapy Meets Stem Cell Yield Goals, But Further Study Needed

June 9th 2023
Article

Recent studies reported a potential reduction in stem cell yields in patients who were exposed to daratumumab prior to stem cell mobilization.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.